1. A composition for administration to an individual in the respiratory tract, comprising an effective amount of one or more agents capable of inhibiting angiogenesis, and / or active anti-cancer agents, and / or anti-metastatic agents for use as a medicament for local inhibition of metastasis in the lung end unit (TLU) , interalveolar septa, pulmonary interstitium and pulmonary parenchyma. 2. The composition of claim 1, wherein an effective amount of one or more agents capable of inhibiting angiogenesis and / or active anti-cancer agents and / or anti-metastatic agents is administered via intratracheal, intrabronchial, intraalveolar or bronchoalveolar administration. The composition of claim 1, wherein one or more agents capable of inhibiting angiogenesis and / or active anticancer agents and / or antimetastatic agents are agents capable of inhibiting expression of a VEGF gene at an mRNA level, for example, siRNA or an antisense anti-VEGF molecule. four. The composition of claim 1, wherein the one or more agents capable of inhibiting angiogenesis and / or the active anti-cancer agents and / or the anti-metastatic agents are agents capable of inhibiting the VEGF receptor. The composition of claim 1, wherein the one or more agents capable of inhibiting angiogenesis and / or the active anti-cancer agents and / or the anti-metastatic agents are a low molecular weight tyrosine kinase inhibitor. The composition according to claim 1, where one or more agents capable of inhibiting angiogenesis, and / or active anti-cancer agents, and / or anti-metastatic agents are agents, with1. Композиция для введения индивидууму в дыхательные пути, включающая эффективное количество одного или более агентов, способных ингибировать ангиогенез, и/или активных противораковых агентов, и/или противометастатических агентов для применения в качестве лекарства для местного ингибирования метастаза в конечной единице легкого (TLU), межальвеолярных перегородках, легочном интерстиции и легочной паре
